Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors.
Despite advances in depression therapy, early treatment discontinuation with antidepressants remains high and contributes to poor clinical outcomes. In clinical trials, treatment discontinuation with controlled-release paroxetine was similar to placebo and significantly better than immediate-release paroxetine. To examine whether this benefit noted in clinical trials translated into longer therapy duration in practice settings, survival-analysis models were constructed to compare the time to treatment discontinuation of controlled-release paroxetine with that of immediate-release selective serotonin-reuptake inhibitors (SSRIs). Survival analysis indicated that patients receiving controlled-release paroxetine were 28% less likely to discontinue therapy during a 180-day period when compared with patients receiving immediate-release SSRIs.
Eaddy
Michael
M
Applied Health Outcomes, Palm Harbor, Florida, USA.
Bramley
Thomas
T
Regan
Tim
T
D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000145:classification; D001008:Anxiety Disorders / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D003710:Demography; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007344:Insurance Claim Reporting; D008297:Male; D008329:Managed Care Programs; D008404:Massachusetts; D017374:Paroxetine / Q000008:administration & dosage* / Q000009:adverse effects; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome
D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors